Makoto Ueno
About
Makoto Ueno is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Makoto Ueno has authored 237 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 160 papers in Oncology, 106 papers in Surgery and 77 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Makoto Ueno's work include Pancreatic and Hepatic Oncology Research (133 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (69 papers) and Cancer Genomics and Diagnostics (38 papers). Makoto Ueno is often cited by papers focused on Pancreatic and Hepatic Oncology Research (133 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (69 papers) and Cancer Genomics and Diagnostics (38 papers). Makoto Ueno collaborates with scholars based in Japan, United States and South Korea. Makoto Ueno's co-authors include Masafumi Ikeda, Junji Furuse, Takuji Okusaka, Chigusa Morizane, Hiroshi Ishii, Satoshi Kobayashi, Nobumasa Mizuno, Do‐Youn Oh, Tatsuya Ioka and Shunsuke Kondo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.
In The Last Decade
Makoto Ueno
221 papers receiving 3.5k citations
Hit Papers
Peers
Makoto Ueno
Tatsuya Ioka Japan
Goro Nakayama Japan
Hans‐Detlev Saeger Germany
Ángela Lamarca United Kingdom
Takashi Oshima Japan
Jean–Luc Van Laethem Belgium
Heinz‐Josef Klümpen Netherlands
Norio Saito Japan
Hirohisa Kitagawa Japan
Manfred P. Lutz Germany
Citations per year, relative to Makoto Ueno Makoto Ueno (= 1×)
peers
Tatsuya Ioka
Countries citing papers authored by Makoto Ueno
Since
Specialization
Citations
This map shows the geographic impact of Makoto Ueno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Makoto Ueno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Makoto Ueno more than expected).
Fields of papers citing papers by Makoto Ueno
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Makoto Ueno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Makoto Ueno. The network helps show where Makoto Ueno may publish in the future.
Co-authorship network of co-authors of Makoto Ueno
This figure shows the co-authorship network connecting the top 25 collaborators of Makoto Ueno. A scholar is included among the top collaborators of Makoto Ueno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Makoto Ueno. Makoto Ueno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dong, Jiahong, Satoshi Ogasawara, Ran Liu, et al.. (2025). LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 36. S62–S62.
2.
Terashima, Takeshi, Kouki Nio, Naohiko Koshikawa, et al.. (2025). Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. PubMed. 3(1). 2–2.
3.
Imaoka, Hiroshi, Masafumi Ikeda, Masato Ozaka, et al.. (2025). Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. European Journal of Cancer. 222. 115424–115424.
4.
Nakachi, Kohei, Masafumi Ikeda, Masaru Konishi, et al.. (2024). Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT.. Journal of Clinical Oncology. 42(16_suppl). 4119–4119.
5.
Washimi, Kota, Yukihiko Hiroshima, Shinya Sato, et al.. (2024). Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Pathology International. 74(5). 252–261.
6.
Kawamoto, Yasuyuki, Yoshito Komatsu, Shunsuke Kondo, et al.. (2024). Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future Oncology. 20(26). 1901–1907.
7.
Furuse, Junji, Masafumi Ikeda, Makoto Ueno, et al.. (2024). A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. Clinical Cancer Research. 30(18). 3990–3995.
8.
Ohba, Akihiro, Chigusa Morizane, Yasuyuki Kawamoto, et al.. (2024). Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology. 42(27). 3207–3217.
9.
Fujiwara, Yutaka, Yasutoshi Kuboki, Masayuki Furukawa, et al.. (2023). FIGHT ‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer Medicine. 12(9). 10597–10611.
10.
Morizane, Chigusa, Nozomu Machida, Yoshitaka Honma, et al.. (2023). 1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213. Annals of Oncology. 34. S709–S709.
11.
Kobayashi, Shogo, Masafumi Ikeda, Masaru Konishi, et al.. (2023). Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202. European Journal of Surgical Oncology. 50(2). 107324–107324.
12.
Sato, Shinya, Masatoshi Nakagawa, Takeshi Terashima, et al.. (2023). EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma. Cancer Research Communications. 3(9). 1862–1874.
13.
Hihara, Fukiko, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.. (2022). In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. International Journal of Molecular Sciences. 23(10). 5807–5807.
14.
Kotani, Daisuke, Masahiro Hattori, Masato Nishihara, et al.. (2022). Rapid Screening Using Pathomorphologic Interpretation to Detect BRAF V600E Mutation and Microsatellite Instability in Colorectal Cancer. Clinical Cancer Research. 28(12). 2623–2632.
15.
Fukushima, Taito, Manabu Morimoto, Makoto Ueno, et al.. (2021). Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting. JGH Open. 6(1). 29–35.
16.
Ueno, Makoto, Y. Sano, Satoshi Tanaka, et al.. (2021). Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis. Cancer Medicine. 11(4). 1088–1098.
17.
Yamamoto, Naoto, Masaaki Murakawa, Toru Aoyama, et al.. (2020). Rapidly progressed neuroendocrine carcinoma in the extrahepatic bile duct: a case report and review of the literature. SHILAP Revista de lepidopterología. 6(1). 191–191.
18.
Kobayashi, Satoshi, Makoto Ueno, Hiroki Hara, et al.. (2016). Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer. Oncology. 91(3). 117–126.
19.
Ohkawa, Shinichi, Yasunari Sakamoto, & Makoto Ueno. (2013). [A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].. PubMed. 40(6). 785–8.
20.
Ueno, Makoto, et al.. (2013). Significance of the perioperative measurement of brain natriuretic peptide (BNP) in general thoracic surgery. The Journal of the Japanese Association for Chest Surgery. 27(1). 3–10.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tatsuya Ioka Breakdown of academic impact, for papers by Goro Nakayama Breakdown of academic impact, for papers by Hans‐Detlev Saeger Breakdown of academic impact, for papers by Ángela Lamarca Breakdown of academic impact, for papers by Takashi Oshima Breakdown of academic impact, for papers by Jean–Luc Van Laethem Breakdown of academic impact, for papers by Heinz‐Josef Klümpen Breakdown of academic impact, for papers by Norio Saito Breakdown of academic impact, for papers by Hirohisa Kitagawa Breakdown of academic impact, for papers by Manfred P. Lutz